G01N 2333/916
Acting on ester bonds
Official title: acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
G01N2333/916 (Acting on ester bonds) appears on 749 US grants and 1,346 published applications in this corpus.
Search patents in G01N- Granted patents
- 749
- Published applications
- 1,346
- Assignees
- 760
- Inventors
- 3,118
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 3 | 0 |
| 1978 | 0 | 0 |
| 1979 | 2 | 0 |
| 1980 | 2 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 1 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 2 | 0 |
| 1988 | 3 | 0 |
| 1989 | 1 | 0 |
| 1990 | 2 | 0 |
| 1991 | 1 | 0 |
| 1992 | 13 | 0 |
| 1993 | 12 | 0 |
| 1994 | 11 | 0 |
| 1995 | 7 | 0 |
| 1996 | 9 | 0 |
| 1997 | 5 | 0 |
| 1998 | 24 | 0 |
| 1999 | 11 | 0 |
| 2000 | 9 | 0 |
| 2001 | 10 | 4 |
| 2002 | 13 | 23 |
| 2003 | 14 | 35 |
| 2004 | 8 | 30 |
| 2005 | 9 | 47 |
| 2006 | 10 | 41 |
| 2007 | 13 | 48 |
| 2008 | 16 | 26 |
| 2009 | 18 | 44 |
| 2010 | 18 | 60 |
| 2011 | 21 | 41 |
| 2012 | 33 | 58 |
| 2013 | 20 | 49 |
| 2014 | 30 | 60 |
| 2015 | 29 | 87 |
| 2016 | 41 | 81 |
| 2017 | 40 | 66 |
| 2018 | 56 | 69 |
| 2019 | 39 | 46 |
| 2020 | 44 | 54 |
| 2021 | 35 | 56 |
| 2022 | 23 | 50 |
| 2023 | 17 | 50 |
| 2024 | 28 | 61 |
| 2025 | 27 | 97 |
| 2026 | 17 | 63 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Modulating human Cas9-specific host immune response29 Sep 2026US 12,747,432 B2Arizona Board of Regents on behalf of Arizona State University
- Materials and methods for detecting and treating autoimmune movement disorders25 Aug 2026US 12,716,893 B2Mayo Foundation for Medical Education and Research
- Compositions and methods for CRISPR/Cas-based gene editing18 Aug 2026US 12,709,743 B2China Agricultural University
- Extraction process of pancrelipase and evaluation thereof18 Aug 2026US 12,710,424 B2Kashiv Biosciences, LLC
- Method for the determination of hydrolytic activity11 Aug 2026US 12,704,518 B2Hoffmann-La Roche Inc.
- Risankizumab compositions1 Oct 2026US 2026/0297178 A1AbbVie Inc.
- Increasing the sensitivity of a crispr-cas nucleic acid detection system1 Oct 2026US 2026/0297656 A1Nederlandse Organisatie voor toegepast-natuurwetenschappelijk onderzoek TNO
- Glycoprotein biomarkers for ovarian cancer diagnosis1 Oct 2026US 2026/0298932 A1Proseek Bio Pty Ltd.
- Risankizumab compositions24 Sep 2026US 2026/0285967 A1AbbVie Inc.
- Inhibitors of ets2-activating molecules for the treatment of inflammatory diseases17 Sep 2026US 2026/0273081 A1The Francis Crick Institute Limited
Most cited
By later US patents
- Methods of producing nucleic acid ligands204US 5,595,877 ANeXstar Pharmaceuticals, Inc. · 1997
- Nucleic acid ligands to HIV-RT and HIV-1 rev178US 5,496,938 ANeXstar Pharmaceuticals, Inc. · 1996
- Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase152US 5,503,978 AUniversity Research Corporation · 1996
- Methods for identifying nucleic acid ligands of human neutrophil elastase115US 5,472,841 ANeXstar Pharmaceuticals, Inc. · 1995
- High affinity ssDNA ligands of HIV-1 reverse transcriptase113US 5,786,462 ANeXstar Pharmaceuticals, Inc. · 1998